Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

Roche Basel Switzerland

FDA grants Roche’s alectinib priority review for lung cancer

Expedited review given for ALK-positive lung cancer treatment

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

- PMLiVE

NICE turns down Celgene’s Otezla once again

Concludes the drug's cost outweighs its benefit for psoriatic arthritis

- PMLiVE

Industry files complaint against France’s off-label law

Protests against promotion of Roche's Avastin as cheap eye medication

- PMLiVE

Roche wins first approval for skin cancer drug Cotellic

Swissregulators give the Exelixis-discovered treatment the green light

Daiichi Sankyo logo

NICE recommends Daiichi Sankyo’s Lixiana for DVT and PE

Institute's final guidance concludes the novel oral anticoagulant is cost effective

- PMLiVE

Pfizer starts Ibrance trials in early breast cancer

Hopes to encourage wider use of breakthrough drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links